Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts less than Nifty Microcap 250 and 6.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gufic Biosciences reported revenue from operations of ₹23,109 lakhs (standalone) for Q3 FY26, up about 11% from ₹20,779 lakhs in Q3 FY25. For the nine months ended December 2025, standalone revenue grew nearly 12% YoY to ₹68,842 lakhs. However, standalone net profit for Q3 FY26 fell to ₹1,556 lakhs (from ₹1,932 lakhs YoY), and 9M FY26 PAT dropped sharply to ₹4,257 lakhs versus ₹6,196 lakhs in 9M FY25 — a roughly 31% decline. The profit pressure came mainly from raw material costs, which surged around 36% YoY over nine months, far outpacing revenue growth. The statutory auditors (Mittal Agarwal & Company) issued an unqualified limited review report. Separately, the Board approved an additional investment of up to USD 50,000 in Australia's Selvax Pty Ltd to subscribe to 3,78,350 ordinary shares at AUD 0.20 per share, as part of its biotech/oncology diversification strategy.
While top-line growth was decent, sharply rising input costs have eaten into margins and caused a meaningful drop in profit — shareholders should expect the stock to react negatively given the steep PAT decline. The small Selvax investment is strategically positive (biotech/oncology exposure) but financially immaterial at this stage.